Estradiol/norethisterone transdermal patch - Johnson & JohnsonAlternative Names: Estradiol + norethisterone transdermal - Johnson & Johnson; Evorel Sequi; Systen Sequi
Latest Information Update: 12 Nov 1998
At a glance
- Originator Johnson & Johnson
- Developer Janssen-Cilag
- Class Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Norpregnenes; Oral contraceptives; Small molecules
- Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Menopausal syndrome; Postmenopausal osteoporosis